[ Corporate » Management ]
Management
PolyMedix is in an advantageous position in that many of its senior management has previously worked together in successful biopharmaceutical endeavors. They form a cohesive, highly productive, and well-experienced team.
The management team members of PolyMedix include:
Nicholas Landekic, has  served
as President, Chief Executive Officer and Director and a Founder of
PolyMedix, Inc. since inception in 2002. Mr. Landekic has more than 20 years of
pharmaceutical experience. From 2000 to 2002, he was President and Chief
Executive Officer of Locus Discovery, during which time the company raised $83
million in financings, built one of the most powerful supercomputer clusters in
the world according to TFCC, and received the accolade “One of the 10 hottest
biotech start-ups” from Drug Discovery Magazine. From 1995 to 2000, Mr. Landekic
was Senior Vice President of Corporate Development & Investor Relations at
Guilford Pharmaceuticals. From 1991 to 1995, Mr. Landekic served as Senior
Director of Business Development at Cephalon and, from 1988 to 1991, served as
Senior Manager for Strategic Marketing at Bristol-Myers Squibb. He also held
positions in Finance and Business Development at Johnson & Johnson Corporation (McNeil
Pharmaceutical) from 1985 to 1988 and positions in the research laboratories at
the Mt. Sinai Medical Center from 1982 to 1983. Mr. Landekic received an M.B.A.
from the State University of New York at Albany, an M.A. in Biology from Indiana
University and a B.S. in Biology from Marist College.
|
J. Gregory Ford, has served as Vice President,  Business
Development of PolyMedix, Inc. since December 2008. Mr. Ford has over 20
years of biotechnology and pharmaceutical experience. Prior to joining
PolyMedix, Mr. Ford was Vice President, Business Development and Strategic
Planning for CollaGenex Pharmaceuticals, Inc., from August 2004 until
November 2008. Prior to CollaGenex Pharaceuticals, Inc., Mr. Ford served as
Vice President, Global Business Development of SkyePharma US Inc. from
February 2003 to April 2004. Prior to SkyePharma US Inc., Mr. Ford served in
various positions of increasing responsibility at SkyePharma Canada, Inc.
and its predecessor RTP Pharma Inc., Boehringer Ingelheim Pharmaceuticals,
Inc., Mylan Laboratories, Inc., and Mylan Pharmaceuticals, Inc. Mr. Ford
received an M.B.A and a B.S. in Industrial Engineering from West Virginia
University.
|
Bozena Korczak, Ph.D., has
served as Vice President, Drug Development of PolyMedix, Inc. since
November 2007. Dr. Korczak has over 20 years of experience in discovery, pre
clinical and clinical research at burgeoning biotechnology organizations.
Prior to joining PolyMedix, Dr. Korczak was a consultant for PharmaReach,
Ltd., a private drug development consulting company, from October 2005 to
November 2007. From September 2001 to October 2005, Dr. Korczak was Vice
President of Research and Development of Cytochroma, Inc., a private
biotechnology company. Prior to Cytochroma, Inc., Dr. Korczak served in
various positions of increasing responsibility at Glycodesign, Inc., Allelix
Biopharmaceutical, Inc. and Mount Sinai Hospital. She is an author of thirty
five peer review scientific papers and holds a Ph.D. in biochemistry from
the Polish Academy of Science.
|
 R.
Eric McAllister, M.D., Ph.D., has served as Vice President, Clinical
Development and Chief Medical Officer of PolyMedix, Inc. since November
2006. Dr. McAllister has over 25 years of industry and clinical trials
experience, most recently from October 2004 to October 2006 as Sr. Vice
President of Clinical Development at CombinatoRx Inc. Prior to that, from
May 2002 to October 2004, Dr. McAllister was Vice President, Clinical
Research with Sicor Pharmaceuticals, Inc. Dr. McAllister has held various
clinical development positions with TAP Pharmaceuticals, Inc., Cholestech
Inc., Bristol Myers Squibb, Co., G.D. Searle and Company, and Syntex
Pharmaceuticals Ltd. Dr. McAllister also spent seven years as a clinical
investigator with MedStudies. He has worked on the development of such major
pharmaceutical products as Lupron, Pravachol, Capoten, Kerlone, Cardene,
Calan, Avandia, Actos, Teveten, and Atacand. Dr. McAllister received his M.D.
from Dalhousie University, and D. Phil. degree from Oxford University, and
was also a Rhodes Scholar. |
Richard W. Scott, Ph.D.,  has
served as Vice President, Research and a Founder of PolyMedix, Inc.
since since November 2002. Dr. Scott has approximately 20 years of
biopharmaceutical industry experience. Most recently, he was Vice President
of Biology at Cephalon, Inc. where he held positions of increasing
responsibility from 1991 to 2001. From 1985 to 1990, Dr. Scott worked at the
research laboratories of DuPont and Company. Dr. Scott has authored more
than 45 papers and book chapters, and is named on six patents. Dr. Scott
holds a Ph.D. in Microbiology from the University of Pennsylvania and a B.S.
in Biology from Muhlenberg College.
|
|
Edward F. Smith,  has
served as Vice President, Finance and Chief Financial Officer of
PolyMedix, Inc. since January 2006. Mr. Smith has approximately 15 years of
combined biopharmaceutical industry and financial management experience.
From 2000 to 2005, he was Executive Director of Finance at InKine
Pharmaceutical Company, Inc. (acquired by Salix Pharmaceuticals, Ltd. in
2005). From 1993 to 1999, Mr. Smith held various positions of increasing
responsibility in public accounting, most recently as a manager in the audit
practice at Deloitte & Touche LLP. Mr. Smith is licensed as a Certified
Public Accountant in Pennsylvania and holds a B.S. degree in Business
Administration from the University of Hartford.
|
return to top ^ |
